Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABY-029 in Primary Soft-tissue Sarcoma
NCT03154411Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Aug 2017
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABY-029 in soft tissue sarcoma (STS), sponsored by Dartmouth Health. Primary endpoint: Signal-to-Noise Ratio at 1 week. Started Aug 2017; status: completed.
02
Drugs
ABY-029
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03154411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154411.